Xavier Madrigal-Sánchez, who operates in the biopharmaceutical sector, was noted for his professional context and the underperformance of the company he is associated with.
2 reports, 1 independent
Updated Aug 1
Gone quiet
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Xavier Madrigal-Sánchez, who operates in the biopharmaceutical sector, was noted for his professional context and the underperformance of the company he is associated with.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Xavier Madrigal-Sánchez
Mexican botanist
Nothing else this week.
Coverage
Newest first; wire copies grouped- ZacksMadrigal (MDGL) Reports Q2 Loss, Tops Revenue Estimates Madrigal (MDGL) came out with a quarterly loss of $1.9 per share versus the Zacks Consensus Estimate of a loss of $3.48. This compares to a los